Tag: NASDAQ: HSTO

Business

Emricasan Found to be Safe and Well Tolerated from its Phase 1 Study Results Announced by Histogen (NASDAQ: HSTO) and Amerimmune

Histogen (NASDAQ: HSTO) opened its doors in 2007 after heeding to the call of a rising need to develop innovative technologies for aesthetic and therapeutic markets. The discovery by the company’s founder, Dr. Gail Naughton, of the potential of proteins and growth factors produced by cells grown under simulated embryonic […]

Business

Histogen Inc. (NASDAQ: HSTO) Jumps 16% After Releasing Promising Phase 1 Emricasan Study Results in COVID-19

Histogen Inc. (NASDAQ: HSTO) jumped 16.16% after the company and Amerimune LLC, its partner, announced the top-line resulted from the phase 1 study assessing emricasan’s safety, preliminary efficacy, and tolerability in the treatment of patients with mild symptomatic COVID-19.  Emricasan shows favorable safety and tolerability profile.  Compared to placebo, emricasan […]